Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. / Jensen, Sanne Brun; Fahnøe, Ulrik; Pham, Long V.; Serre, Stéphanie Brigitte Nelly; Tang, Qi; Ghanem, Lubna; Pedersen, Martin Schou; Ramirez, Santseharay; Humes, Daryl; Pihl, Anne Finne; Filskov, Jonathan; Sølund, Christina Søhoel; Dietz, Julia; Fourati, Slim; Pawlotsky, Jean Michel; Sarrazin, Christoph; Weis, Nina; Schønning, Kristian; Krarup, Henrik; Bukh, Jens; Gottwein, Judith Margarete.
In: Hepatology, Vol. 70, No. 3, 2019, p. 771-787.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
AU - Jensen, Sanne Brun
AU - Fahnøe, Ulrik
AU - Pham, Long V.
AU - Serre, Stéphanie Brigitte Nelly
AU - Tang, Qi
AU - Ghanem, Lubna
AU - Pedersen, Martin Schou
AU - Ramirez, Santseharay
AU - Humes, Daryl
AU - Pihl, Anne Finne
AU - Filskov, Jonathan
AU - Sølund, Christina Søhoel
AU - Dietz, Julia
AU - Fourati, Slim
AU - Pawlotsky, Jean Michel
AU - Sarrazin, Christoph
AU - Weis, Nina
AU - Schønning, Kristian
AU - Krarup, Henrik
AU - Bukh, Jens
AU - Gottwein, Judith Margarete
PY - 2019
Y1 - 2019
N2 - Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance determinants is highly relevant for efforts to control HCV. Here, we investigated patterns of PI resistance–associated substitutions (RASs) for the major HCV genotypes and viral determinants for persistence of key RASs. We identified protease position 156 as a RAS hotspot for genotype 1-4, but not 5 and 6, escape variants by resistance profiling using PIs grazoprevir and paritaprevir in infectious cell culture systems. However, except for genotype 3, engineered 156-RASs were not maintained. For genotypes 1 and 2, persistence of 156-RASs depended on genome-wide substitution networks, co-selected under continued PI treatment and identified by next-generation sequencing with substitution linkage and haplotype reconstruction. Persistence of A156T for genotype 1 relied on compensatory substitutions increasing replication and assembly. For genotype 2, initial selection of A156V facilitated transition to 156L, persisting without compensatory substitutions. The developed genotype 1, 2, and 3 variants with persistent 156-RASs had exceptionally high fitness and resistance to grazoprevir, paritaprevir, glecaprevir, and voxilaprevir. A156T dominated in genotype 1 glecaprevir and voxilaprevir escape variants, and pre-existing A156T facilitated genotype 1 escape from clinically relevant combination treatments with grazoprevir/elbasvir and glecaprevir/pibrentasvir. In genotype 1 infected patients with treatment failure and 156-RASs, we observed genome-wide selection of substitutions under treatment. Conclusion: Comprehensive PI resistance profiling for HCV genotypes 1-6 revealed 156-RASs as key determinants of high-level resistance across clinically relevant PIs. We obtained in vitro proof of concept for persistence of highly fit genotype 1-3 156-variants, which might pose a threat to clinically relevant combination treatments.
AB - Protease inhibitors (PIs) are important components of treatment regimens for patients with chronic hepatitis C virus (HCV) infection. However, emergence and persistence of antiviral resistance could reduce their efficacy. Thus, defining resistance determinants is highly relevant for efforts to control HCV. Here, we investigated patterns of PI resistance–associated substitutions (RASs) for the major HCV genotypes and viral determinants for persistence of key RASs. We identified protease position 156 as a RAS hotspot for genotype 1-4, but not 5 and 6, escape variants by resistance profiling using PIs grazoprevir and paritaprevir in infectious cell culture systems. However, except for genotype 3, engineered 156-RASs were not maintained. For genotypes 1 and 2, persistence of 156-RASs depended on genome-wide substitution networks, co-selected under continued PI treatment and identified by next-generation sequencing with substitution linkage and haplotype reconstruction. Persistence of A156T for genotype 1 relied on compensatory substitutions increasing replication and assembly. For genotype 2, initial selection of A156V facilitated transition to 156L, persisting without compensatory substitutions. The developed genotype 1, 2, and 3 variants with persistent 156-RASs had exceptionally high fitness and resistance to grazoprevir, paritaprevir, glecaprevir, and voxilaprevir. A156T dominated in genotype 1 glecaprevir and voxilaprevir escape variants, and pre-existing A156T facilitated genotype 1 escape from clinically relevant combination treatments with grazoprevir/elbasvir and glecaprevir/pibrentasvir. In genotype 1 infected patients with treatment failure and 156-RASs, we observed genome-wide selection of substitutions under treatment. Conclusion: Comprehensive PI resistance profiling for HCV genotypes 1-6 revealed 156-RASs as key determinants of high-level resistance across clinically relevant PIs. We obtained in vitro proof of concept for persistence of highly fit genotype 1-3 156-variants, which might pose a threat to clinically relevant combination treatments.
U2 - 10.1002/hep.30647
DO - 10.1002/hep.30647
M3 - Journal article
C2 - 30964552
AN - SCOPUS:85071462326
VL - 70
SP - 771
EP - 787
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 3
ER -
ID: 227474254